Bernstein's Anderson expects 'long, slow' exit from woes at AstraZeneca; Reviva raises $12M;

 @FierceBiotech: Cerulean Pharma's lead nanodrug crashes in lung cancer study. News | Follow @FierceBiotech

@JohnCFierce: No decision yet, but Soriot at AstraZeneca certainly sounds like he's going to do a biosimilars move. More | Follow @JohnCFierce

@RyanMFierce: No surprises here. BG-12 gets nod from EMA committee as first-line MS therapy. Release | Follow @RyanMFierce

> Altas Venture Managing Partner Bruce Booth blogs about upbeat biotech deals trends by the numbers. Item

> With assets from Belgian biotech Galapagos, Cambridge, MA-based DART Therapeutics aims to develop new treatments for Duchenne muscular dystrophy. Release

> Reviva Pharmaceuticals, a West Coast biotech with an interest on schizophrenia, has found $12 million from investors. Article

> Merck's ($MRK) financial chief Peter Kellogg talks about keeping an eye on budget for one of the world's biggest R&D spenders. More

Pharma News

@FiercePharma: Vietnam drug spending makes it a prime pharma target. Article | Follow @FiercePharma

@EricPFierce: Inspection report details why Hospira's hopes were recently dashed by the FDA. Story | Follow @EricPFierce

> EMA recommendation gives Sanofi's MS drug Aubagio another boost. More

> J&J fights $327M Risperdal verdict, saying no one was harmed. Story

Medical Device News

 @FierceMedDev: If you missed our special report yesterday: Med Tech's 2012 R&D big spenders. More | Follow @FierceMedDev

 @MarkHFierce: Big win for GE--expanded FDA approval for an imaging agent, now to gauge risk of death in heart failure patients. Release | Follow @MarkHFierce

 @DamianFierce: Feds: The worry about device tax/regulatory slowdown for mobile apps is mostly hot air. More | Follow @DamianFierce

> 'Symbolic' device tax repeal vote passes in U.S. Senate. More

> Swiss team envisions cheap, durable Dx imaging for Africa. Article

> Study: Asuragen's molecular Dx better at Fragile X detection. Story

And Finally… Top pharma industry analyst Tim Anderson of Bernstein predicts a "long, slow crawl" out from under numerous problems at AstraZeneca ($AZN) after company CEO Pascal Soriot's big reorganization announced this week. Item